Cumberland Pharmaceuticals secured a new supply arrangement for its FDA-approved product, Vibativ.
2 reports, 1 independent
Updated Aug 6
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cumberland Pharmaceuticals secured a new supply arrangement for its FDA-approved product, Vibativ.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Cumberland Pharmaceuticals (United States)
company in Nashville Tennessee United States
Nothing else this week.
Related events
- Vitruvias Therapeutics, based in Auburn, Alabama, has received a recall notice from the FDA for its medication.
- Teva's acquired product is currently undergoing review by the FDA.
- A product was launched in the U.S. market following FDA involvement.
- An experimental drug, sourced from China, is under FDA scrutiny after marketing claims of being 'the ultimate good' and subsequent warnings were issued.
- On August 28, 2026, the FDA approved Moderna's mNEXSPIKE vaccine and gave the green light to Novavax's Nuvaxovid vaccine. Separately, ProFound Therapeutics was formed by Flagship Pioneering.
Coverage
Newest first; wire copies grouped- PR NewswireCumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, a
- PR NewswireCUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers N